Alan B Lancz & Associates Inc. Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Alan B Lancz & Associates Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 10.5% during the fourth quarter, HoldingsChannel reports. The firm owned 19,205 shares of the biopharmaceutical company’s stock after selling 2,250 shares during the period. Alan B Lancz & Associates Inc.’s holdings in Pfizer were worth $553,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Briaud Financial Planning Inc acquired a new position in Pfizer in the 3rd quarter worth $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the third quarter valued at $34,000. VisionPoint Advisory Group LLC lifted its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer in the 4th quarter worth about $36,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PFE shares. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley raised their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday. Finally, Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.00.

Pfizer Stock Up 0.4 %

Shares of NYSE PFE traded up $0.11 during mid-day trading on Friday, reaching $27.81. The company had a trading volume of 60,568,852 shares, compared to its average volume of 41,900,304. The stock has a fifty day moving average of $26.88 and a two-hundred day moving average of $28.21. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The company has a market capitalization of $157.48 billion, a price-to-earnings ratio of -463.42, a PEG ratio of 1.18 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The company’s revenue was down 19.5% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.36 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.